A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer
Dae Won Kim, Elaine Tan, Junmin Zhou, Michael J. Schell, María Carmen Riesco Martínez, James Yu, Estrella M. Carballido, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Richard D. Kim
Topics & Concepts
MedicineIbrutinibPembrolizumabInternal medicineOncologyColorectal cancerPhases of clinical researchClinical endpointAdverse effectClinical trialCancerImmunotherapyLeukemiaChronic lymphocytic leukemiaCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment